Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

13th Asia-Pacific Oncologists Annual Meeting

Kualalumpur, Malaysia

Craig Pierson

Craig Pierson

ArcherDX Inc., USA

Title: Comprehensive detection of expressed mutations by anchored multiplex PCR and next-generation sequencing

Biography

Biography: Craig Pierson

Abstract

The landscape of driver mutations in cancer encompasses many types of mutations occurring across many genes. These include copy number variants (CNVs), single nucleotide variants (SNVs), insertions and deletions (indels), exon skipping and gene fusions. Traditional molecular testing to detect each of these mutation types in clinical samples cannot be easily coupled to detect all possible mutation types in a single sample. Next-generation sequencing (NGS) on whole transcriptome (RNA-Seq) enables comprehensive profiling of expressed mutations. However, low sensitivity and high cost renders RNA-Seq impractical for routine clinical use. Target-enrichment strategies for NGS, such as Anchored Multiplex PCR (AMP™), increase read depth and enhance sensitivity. AMP uses unidirectional gene-specific primers and molecular barcoded adapters ligated to DNA ends for amplification. This enables amplification of both known and unknown mutations and increases coverage of target regions. We developed AMP-based Archer® FusionPlex® assays to detect the presence and expression of known and novel SNVs, indels, exon skipping and fusions from RNA transcripts. Here, we used FusionPlex assays to detect each mutation type in RNA extracted from clinical sample types, including: EGFR L858R SNV in a non-small cell lung cancer (NSCLC) FFPE sample; FLT3 internal tandem duplications (ITDs) in acute myeloid leukemia (AML) blood samples; MET exon 14 skipping in NSCLC FFPE samples and; EML4-ALK fusion in an NSCLC FFPE sample by breakpoint identification and expression imbalance. Together, these results demonstrate that FusionPlex assays enable comprehensive NGS-based detection of expressed mutations in RNA extracted from clinical sample types.